Blog

SAN DIEGO, CALIFORNIA / ACCESS Newswire / December 1, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing inflammation, today announced it has successfully reached a quorum for its Special Meeting scheduled for December 3, 2025. As a reminder, if you have not yet voted you have until 11:59pm ET tomorrow, December 2, 2025, to vote.

“I would like to thank all those that have voted for the December 3, 2025, Special Meeting and remind all those who have not yet voted to vote,” said James Rolke, Chief Executive Officer, Revelation.

On November 20, 2025, Revelation Biosciences announced its successful submission and acceptance of the end-of-phase 1 meeting package to FDA, and that the company is on track to hold the meeting later this year. The primary purpose of this meeting is to establish agency feedback and input into the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury (AKI).

On November 6, 2025, the company reported its financial results for the three and nine months ended September 30, 2025. Highlights include groundbreaking top-line results from the PRIME clinical study and gross proceeds of $9.6 million from warrant inducement in September 2025.

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including the treatment of chronic kidney disease, prevention for post-surgical infection and as a treatment for acute kidney injury.

For more information on Revelation, please visit www.RevBiosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

Company Contact

Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: mike@plrinvest.com

Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com

SOURCE: Revelation Biosciences, Inc.

View the original press release on ACCESS Newswire

RALEIGH, NC / ACCESS Newswire / December 1, 2025 / iAccess Alpha’s Virtual Best Ideas Winter Investment Conference will take place on December 9-10, 2025, bringing together top micro-cap companies and investors for two days of high-quality insights and investing opportunities.

The event begins on Tuesday, December 9, 2025, with a series of live-streamed company presentations, beginning at 9:00 AM ET. The following day, Wednesday, December 10, will be dedicated to 1×1 meetings between presenting companies and pre-approved investors, starting at 8:00 AM ET.

How to Attend:

Investors and industry professionals can register to watch the presentations and request 1×1 meetings by visiting the official event website: Register Here

Conference Schedule – December 9, 2025 (All Times ET):

Time	Company	Ticker	Webcast Link
9:00am	Digi Power X Inc.	NASDAQ: DGXX – TSXV: DGX	View Presentation
9:30am	Dyadic International Inc.	NASDAQ: DYAI	View Presentation
10:00am	Strattec Security Corp	NASDAQ: STRT	View Presentation
10:30am	GameSquare Holdings Inc.	NASDAQ: GAME	View Presentation
11:00am	Birchtech Corp	OTCQB: BCHT	View Presentation
11:30am	WidePoint Corporation	NYSE AMEX: WYY	View Presentation
12:00pm	Ascent Industries Co.	NASDAQ: ACNT	View Presentation
12:30pm	RenovoRx Inc.	NASDAQ: RNXT	View Presentation
1:00pm	DocGo Inc.	NASDAQ: DCGO	View Presentation
1:30pm	B.O.S. Better Online Solutions Ltd.	NASDAQ: BOSC	View Presentation
2:00pm	Scienture Holdings, Inc.	NASDAQ: SCNX	View Presentation
2:30pm	Elauwit Connection Inc.	NASDAQ: ELWT	View Presentation
3:00pm	Mobilicom Ltd ADR	NASDAQ: MOB	View Presentation

About iAccess Alpha’s Virtual Best Ideas Investment Conferences

iAccess Alpha hosts four virtual investment conferences annually (March, June, September, and December), showcasing high-potential small and micro-cap investment opportunities. The conferences feature live company presentations on Day 1, followed by exclusive 1×1 investor meetings on Day 2. Since 2019, iAccess Alpha has co-organized leading microcap-focused events, connecting top-tier investors with high-potential companies.

For more information, contact:

info@iaccessalpha.com
www.iaccessalpha.com

SOURCE: iAccess Alpha

View the original press release on ACCESS Newswire

Newly created role to accelerate AmeriLife’s digital transformation and enhance technology integration across the company’s expansive affiliate network

CLEARWATER, FL / ACCESS Newswire / December 1, 2025 / AmeriLife Group, LLC (“AmeriLife”), a national leader in life and health insurance distribution, wealth management, and retirement solutions, today announced the appointment of Sulabh Srivastava as its Chief Information Officer (CIO). Srivastava will report to AmeriLife’s Chief Operating Officer, Tim Calvert.

This strategic role underscores AmeriLife’s commitment to transforming its technology to accelerate growth and transformation. Srivastava will lead AmeriLife’s enterprise technology organization, driving innovation and further unifying its agile platform to support the company’s expanding portfolio of affiliate companies.

Srivastava brings more than two decades of experience leading enterprise-wide transformations at high-growth, complex organizations. As Global CIO of Acrisure, he built scalable technology infrastructure, cybersecurity operations, and IT systems across global markets. He drove AI and automation strategies that delivered measurable improvements in efficiency and data-driven decision-making. Earlier, at Indiana University Health and University of Michigan Health-Sparrow, he led award-winning digital initiatives, including electronic medical records systems that set industry benchmarks.

“Technology continues to be central to AmeriLife’s ability to scale and deliver exceptional experiences for our affiliate partners and their agents,” said Calvert. “Sulabh’s proven track record in accelerating digital transformation and leading high-performing teams makes him uniquely positioned to transform our technology capabilities for the future.”

Srivastava holds a Bachelor of Engineering from Visvesvaraya National Institute of Technology and an MBA from Michigan State University’s Eli Broad College of Business. Throughout his career, he has consistently aligned technology strategy with business growth objectives, delivering measurable results and competitive advantage.

“I’m thrilled to join AmeriLife at such a pivotal moment in its evolution,” said Srivastava. “AmeriLife’s platform approach and commitment to empowering its affiliates creates tremendous opportunity for technology-driven innovation. I look forward to working alongside our leadership team and technology organization to build transformative solutions that accelerate growth and create lasting value for our partners, agents, and customers.”

About AmeriLife

AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. AmeriLife develops, markets, and distributes life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For over 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers through a national distribution network of over 300,000 agents, financial professionals, and more than 160 marketing organizations and insurance agencies. For more information, visit AmeriLife.com and follow AmeriLife on Facebook and LinkedIn.

SOURCE: AmeriLife

Related Images

View the original press release on ACCESS Newswire

SHELTON, CONNECTICUT / ACCESS Newswire / December 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has signed a Master Services Agreement (MSA) with Only Orphans Cote, LLC, (“OOC”) a regulatory consultant firm founded by Dr. Timothy Cote. Dr. Cote and OOC will help the Company formulate its orphan drug strategy for NV-387, as well as develop relevant orphan drug designation applications and prosecute these applications at the US FDA Office of Orphan Products.

“In earlier discussions with Dr. Cote, it became apparent that the broad-spectrum antiviral drug NV-387 could harness several benefits from an orphan drug regulatory strategy,” said Anil R. Diwan, PhD, President & Executive Chairman of the Company.

NV-387 has demonstrated excellent activity against lethal animal models of orthopoxvirus ectromelia infections in mice. This opens up the regulatory pathway for licensure of NV-387 for the treatment of Smallpox. NV-387 for the treatment of Smallpox is expected to be eligible for an “Orphan drug” designation by the US FDA. Smallpox, eradicated globally in 1980, is considered an important bioterrorism threat.

Additionally, MPox disease caused by the Monkeypox virus, MPXV, a related orthopoxvirus, is considered an “orphan disease” in the USA. Therefore, we believe that NV-387 for the treatment for MPox will be eligible for orphan drug designation.

Further, NV-387 is the only drug candidate to our knowledge that has demonstrated in vivo activity against the Measles virus in a humanized animal model study. Measles infection in the USA is considered an “orphan disease” due to the small number of cases. Therefore, we believe that NV-387 for the treatment for Measles will be eligible for orphan drug designation.

Orphan drug designation qualifies sponsors for incentives including:

• Tax credits for qualified clinical trials;

• Exemption from user fees;

• Potential seven years of market exclusivity after approval;

according to the US FDA (https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products).

Measles cases are rising across the Western world. The USA is likely to lose its Measles elimination status in 2026, if the current outbreak that began in Texas in January 2025 continues through the whole year. Canada has already lost its Measles elimination status. This means Measles is now considered endemic in Canada, and will likely be considered to be endemic in the USA as well. As of November 25, 2025, a total of 1,798 confirmed measles cases were reported in the United States, in 46 outbreaks, across 42 states, according to the CDC (https://www.cdc.gov/measles/data-research/index.html).

NV-387 is an unusually broad-spectrum antiviral drug that has demonstrated strong effectiveness in relevant animal models of multiple human viral infections. These include RSV, COVID, Influenza, Mpox, Smallpox, and Measles.

Dr. Timothy Cote previously served as the Director of US FDA Office of Orphan Products Development (OOPD), and has intimate knowledge of the laws, rules, and regulations, governing orphan drugs, and the potential benefits to the Drug Sponsors.

Viruses crossing over newly into humans from other species do so only upon acquiring significant ability to bind to HSPG, the cell-side molecule that NV-387 mimics as a decoy for the viruses ^[1] . It is highly unlikely that bioterrorism agents would be created that can drastically infect humans and yet do not bind to HSPG.

To date, pandemic preparedness has been dominated by one-drug-one-bug philosophy. With hundreds of potential biothreats, such a strategy is too expensive and would not realize a highly effective protective shield against potential pandemics.

Besides, the medical countermeasures pursued to-date for pandemic preparedness are severely lacking in that every one of them would be readily defeated by the virus as it mutates or evolves in the field. This is one lesson that has become starkly clear after the COVID-19 pandemic.

NV-387 is expected to provide a low cost option for pandemic preparedness against a multiplicity of threats, and could become an effective first response drug for practically any viral pandemic. Over 90% of viruses that can cause disease in humans are known to bind to HSPG. Our development of NV-387 suggests that most of these viruses would be susceptible to NV-387. Moreover, escape from NV-387 is highly unlikely because even as viruses mutate or evolve, they continue to bind well to HSPG as long as they are pathogenic in humans.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide^™ class of drug candidates and the nanoviricide^™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.co

---

^[1] It has been reported that highly pathogenic duck influenza viruses that lack or substantially lack HSPG binding ability do not cause significant pathology in other birds, nor in humans. They appear to use exclusively sialic acid-related receptors and yet have failed to infect other species. We believe these results require further investigation.

SOURCE: NanoViricides

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / December 1, 2025 / There is a shift in global commerce that most companies have not yet caught up to. Markets are starting to wake up to the idea that verification is no longer a back-office function. It’s a new economic layer that determines pricing power, trust, and access. The companies that can prove the truth of their materials, products, and supply chains are beginning to outperform the ones that cannot. SMX (NASDAQ:SMX) sits at the center of that shift. It built a physical-to-digital identity platform that embeds verification into the material itself, transforming proof from a document into an attribute. Companies are discovering that this is the difference between participating in the modern economy and being priced out of it.

The traditional model relied on paperwork, audits, and downstream checks. That structure worked when supply chains were slower and markets were smaller. It collapses in a world where metals flow across continents in days, recycled plastics change hands multiple times before reaching manufacturers, and national security regulations force companies to prove the origin of what they use. The verification gap widened faster than older systems could adapt. SMX stepped into that gap with a system that assigns a molecular-level identity to raw materials, recycled feedstocks, and finished goods. Instead of trying to verify truth at the end of a process, SMX lets companies attach truth at the beginning.

This shift is creating measurable advantages. A verified material commands a premium because buyers know what they are buying. A verified supply chain reduces insurance and regulatory exposure by changing the risk profile. A verified sustainability claim carries weight because it is anchored in a trail no one can alter. Markets reward certainty, and for the first time, certainty scales. Companies that align verification with production gain a clearer picture of their operations and the ability to move faster without getting trapped in audit bottlenecks.

Verification Becomes a Commercial Advantage

One reason verification is emerging as an economic force is that global supply chains have outgrown trust-based systems. Buyers want to know where metals come from, how recycled plastics were processed, and whether critical minerals meet new regulatory thresholds. When companies cannot answer those questions with evidence, they lose leverage. When they can, they gain it. SMX changes the power dynamic. It gives companies the ability to present material truth as data, not opinion.

This matters in markets where origin, purity, and processing history shape value. A verified load of alloy metals can move through customs faster because the documentation is supported by embedded identity. Recycled PET with certified authenticity sells at higher margins because buyers trust the content. A shipment of critical minerals that can demonstrate provenance avoids delays that drive up cost. These are not theoretical benefits. They are structural advantages that compound over time.

The companies adopting verification early are positioning themselves as premium suppliers. They reduce disputes. They shorten sales cycles. They meet regulatory requirements more easily. SMX’s technology does not replace the supply chain. It elevates it. It turns verification into a driver of growth rather than a cost center that reacts to problems after they occur.

The Next Layer of Economic Infrastructure

As verification becomes embedded in materials, it behaves like infrastructure. It unlocks new pricing models. It creates new categories of certified content. It helps governments enforce regulations without slowing down commerce. The effect is similar to what happened when digital payments moved from novelty to necessity. What started as an innovation became a baseline expectation. Verification is on that same trajectory.

Companies are recognizing they can no longer rely solely on claims. Regulators are enforcing accuracy. Customers are asking deeper questions. Investors are demanding transparency. Verification used to be a defensive function. SMX is turning it into an offensive one. It enables companies to demonstrate truth without negotiation and to track materials across their entire lifecycle.

As this shift continues, the companies that embed verification into their operations will shape the markets they participate in. The ones that don’t will fall behind. The verification economy is emerging as one of the defining competitive forces of the next decade. SMX built the framework, and now the world is beginning to realize how valuable it is.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

Contact: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / December 1, 2025 / Modern supply chains used to be simple. A product moved from one place to another, someone signed a form, and the system accepted that as truth. That world doesn’t exist anymore. Global regulations hardened, materials started crossing borders at record speed, and companies faced exposure from every direction. A supply chain without intelligence isn’t a supply chain. It’s a liability. SMX (NASDAQ:SMX) stepped into this environment with a technology that gives materials something they’ve never had. They get memory. They carry their identity from the moment they’re created until the moment they’re used.

Companies are learning the hard way that they can’t navigate global markets with blind spots. Origin matters. Purity matters. Recycled content matters. Compliance matters. A shipment that enters a port with missing data can jam an entire production cycle. When information breaks, business breaks. SMX solves that problem by embedding a molecular-level identity into metals, plastics, textiles, and industrial materials. It works in real conditions because it doesn’t rely on tags or labels that fall off halfway through transit. It’s built inside the material itself, so the identity survives heat, pressure, reforming, and processing. That’s what turns the supply chain into an intelligence network. Companies stop guessing and start knowing.

This shift isn’t theoretical. It’s already showing up in places where trust gaps were the biggest. The partnership with REDWAVE connected SMX’s material identity system to one of the world’s most advanced recycling-sorting technologies. Suddenly, waste streams didn’t look like chaos anymore. The system knew what each batch contained, where it came from, and how it needed to be processed.

When Materials Tell the Truth

In the United States, SMX’s collaboration with Tradepro intends to give manufacturers access to verified recycled plastics instead of hoping a supplier’s paperwork matched reality. These aren’t small moves. They show how supply chains can function with intelligence built in rather than applied after the fact.

That addition fixes the biggest flaw in legacy supply chains: Materials couldn’t speak for themselves. Everyone else speaks on their behalf. A certificate claims a metal is pure. A document claims a shipment is compliant. A sustainability report claims a product meets recycled content targets. None of those claims survives scrutiny if they aren’t backed by evidence. SMX solves that by letting materials carry their own truth. When a metal, polymer, or feedstock enters a system with its identity locked in, nobody has to argue about what it is. That eliminates layers of friction that companies didn’t even realize were costing them money.

This works because SMX aligns verification with production. Instead of checking materials at the end of the line, the company lets manufacturers embed identity at the start. When the A*STAR program in Singapore integrated SMX’s technology into national-scale plastic circularity pilots, it wasn’t just about recycling. It was about tracking materials across collection, processing, reuse, and manufacturing with real evidence. A supply chain becomes intelligent the moment every stop along the route can confirm exactly what it’s handling. That clarity changes behavior. It reduces fraud because fraud becomes pointless. It reduces waste because waste becomes trackable. It reduces delays because data becomes immediate.

Supply chains don’t need more dashboards or more reports. They need truth at the source. When materials carry intelligence, the entire system becomes more efficient. Manufacturers run cleaner lines. Regulators get transparency instead of estimates. Investors cut risk because they can evaluate what’s real without negotiating it. Supply chains stop being fragile networks held together with paperwork. They become living systems where information moves with the material, not behind it.

Where the Intelligence Network Goes Next

Once companies see how intelligent supply chains behave, they don’t want to go back. They start demanding verified inputs. They start rewarding suppliers who can prove content and origin. They start restructuring procurement around materials that carry their own evidence. This isn’t just a shift in logistics. It’s a shift in power. The companies with verified supply chains can move faster, comply more easily, and price more accurately. They compete with confidence while everyone else hopes their documentation holds up under pressure.

The next wave of this transformation will reach industries that haven’t updated their verification models in decades. Metals, plastics, textiles, and industrial feedstocks are only the beginning. SMX’s proof layer gives them all a way to function in a global environment where accuracy is currency. The intelligence travels with the material, not with a binder of certificates. That’s why this shift is accelerating. And it’s also why stakeholders are taking notice. Materials are finally telling the truth about themselves, and companies are building their future operations around that clarity.

Supply chains aren’t supply chains anymore. They’re intelligence networks. And the companies that treat them that way are the ones rewriting the rules of global trade. SMX didn’t just see that shift coming. It engineered the technology that makes it real.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

Contact: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

NORTH YORK, ON / ACCESS Newswire / December 1, 2025 / ZTEST Electronics Inc. (“ZTEST” or the “Company“) (CSE:ZTE)(OTCID:ZTSTF) announces Q1 2026 revenues of $1,823,428, a decrease of 9.7% from Q1 2025. Though, the Company is very encouraged that the second fiscal quarter has started quite strongly, with orders for new boards increasing, providing solid indications that market confidence may be returning.

Financial Highlights		Three months ended
(in thousands of dollars, except per share amounts)		Sept 30 2025				Sept 30 2024
Revenue			1,823				2,020
Gross Margin			778				921
Gross Margin as a % of Revenue			42.7	%			45.6	%
EBITDA			404				519
Net Income			237				324
Basic Net Income per share			0.006				0.009
Operating Cash Flow			323				442

		As at
(in thousands of dollars)		Sept 30 2025				Sept 30 2024
Cash			4,268				3,259
Working Capital			5,324				3,986
Long-term Debt			39				105
Shareholders’ Equity			6,050				4,871

Steve Smith, CEO commented, “In the first quarter, inventory values rose almost 34% to $1.40 million, the highest inventory value since Q3 2024, a definitive indication of improving customer confidence.

We continue to lay a solid foundation, fully anticipating to capitalize on the recovering market, while also diligently assessing our overall business risks. This is clearly demonstrated through our continuous growth in cash, working capital, capital under management, and consistent and reliable gross margins.”

About ZTEST Electronics Inc.

ZTEST Electronics Inc., through its wholly owned subsidiary Permatech Electronics Corporation (“Permatech”), offers Electronic Manufacturing Services (EMS) to a wide range of customers. Permatech’s offering includes Printed Circuit Board (PCB) Assembly, Materials Management and Testing services. Permatech operates from an ISO 9001:2015 certified facility in North York, Ontario, Canada. Permatech is a contract assembler of complex circuit boards, serving customers in the Medical, Power, Computer, Telecommunications, Wireless, Industrial, Trucking, Wearables and Consumer Electronics markets. It specializes in servicing customers who are looking for high yield and require high quality and rapid-turnaround on low and mid-volume production of high complexity products.

For more information contact: Steve Smith, CEO (604) 837-3751 email: steves@ztest.com

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

FORWARD LOOKING STATEMENTS: This press release contains forward looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Investors are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances. All of the forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR+ in Canada (available at www.sedarplus.com).

SOURCE: ZTEST Electronics Inc.

View the original press release on ACCESS Newswire